Freeport stem cell therapy provider Okyanos in wind-up petition battle – EyeWitness News

NASSAU, BAHAMAS The fate of Freeports pioneering stem cell therapy provider has now become the subject of legal dispute, with its principal creditor seeking the winding-up of the company.

According to court documents seen by Eyewitness News, Okyanos claims that damagessuffered toits nearly 15,000 sq feet rented Freeport facilities as a result of Hurricane Dorian in September 2019 left thepremisesunfit for use. As a consequence, all of thecompanysbusiness ceased. That claim however has beenfiercely disputed by its landlord First Commercial Ltd who is seeking to have its dispute arbitrated and block the removal of the companys equipment which could satisfy an award in those proceedings.

Okyanos is the first licensed stem cell therapy provider in The Bahamas. It has been treating patients with chronic diseases by using their own stem cells from fat tissue. It opened to patients in October 2014, providing treatment for those with autoimmune, orthopaedic, cardiovascular and neurological conditions.

According to details outlined in a wind-up petition by its primary creditor LS Enterprise Ltd, -a companyregisteredin the British Virgin Islands, Okyanos between August 2, 2017 and May 6 2019 entered into four loanfacilityagreementsfor working capital and generalcorporate amounting to some $15.9 million. Okyanos had ultimately sought additional loans from LS Enterprise Ltd following Hurricane Dorian however was informed that it was in default of its facility agreements having ceased to carry on its business and that all loans were immediately due and payable.

According to the wind-up petition an ex parte order obtained by Okyanoss landlord First Commercial Ltd had restrained the stem cell therapy provider fromremediatingthepremisesor removing its equipment. It is claimed that substantial amounts of water and wind had penetrated the companyspremises causing major property loss and damage.Further, a lack of consistent electricity and airconditioninghad caused mold contamination.

Thecompanyattemptedtomitigateloss and damage by movingequipmentto aclimatecontrolledstorage and and preparing thecompanysoperatingfacilitiesfor moldremediation butthat was hampered by the landlord whose servants oragentsinstructed thecompanys personnel to cease anddeistfrom such activities, LS Enterprise outlined in its petition.

It further noted that in a notice to the landlord dated October 25, 2019, Okyanos had exercised its right to terminate its leaseagreementwithin 60 daysfollowingthe storm due to the facilities being unfit for use or occupancy the hurricane. On October 30, First Commercial Ltd obtained an ex parte order restraining the company from anyfurtherremediation efforts as well as the removal or disposal of equipment, LS Enterprise has claimed. The company had filed for damages with its insurance provider but had not received the majority of any such insurance proceeds the petition station.

Accordingly it is claimed that the company has insufficient funds to secure a new lease forfacilitiesto treatpatients,arbitratewith landlord torecover itsequipment and supplies, or conduct amarketingcampaignto attract patients to The Bahamas.

However, an affidavit but attorney Andre Jay Feldman, president and a member of the Board of Directors of First Commercial Centre seeking to restrain Okyanos from breaching its lease disputed the companys damages claim.

According to Mr Feldmans affidavit, a copy of which was seen by Eyewitness News, he inspected thepremiseson September 4 and beyond some minimal damage due to a single window having opened in one of theclinicalrooms, there was no damagewhatsoeverthroughoutthe clinic and nosignificantdamage referred to by the company. Mr Feldman claimed that Steve Araiza, a Houston based attorney for Okyanos had written him on September 26, 2019 seeking a rent abatement and to end theleaseon thegrounds of hurricane damage.

According to Mr Feldman, flood water had entered parts of theground flooroccupiedby CIBC and on September 15, 2019, the bank had not onlyremediatedany damage but hadreopenedfor business. He further contended that on September 4, Okyanos had allowed the Rand Memorial Hospital to use itsfacilities for urgent patient care. Mr Feldman contends that there was no damage to make the facilities unfit for use. According to Mr Feldman, since September 1 there had been no payment towards rent or electricity with respect to air-conditioning consumption. He asserted that if Okyanos is allowed to remove its assets they would be shipped out of country and would not be available to satisfy any award from arbitration. The landlord is claiming it is owed $1,768,000 and that while it plans to claim on a $890,000 loss of rentinsurancethere is no guarantee that can be recovered.

View post:
Freeport stem cell therapy provider Okyanos in wind-up petition battle - EyeWitness News

Dementia Live and ‘Stem Cell Therapy for Stroke and Traumatic Brain Injury Patients’ seminars – Trumbull Times

Published 7:30am EST, Monday, February 3, 2020

Bridges by EPOCH at Trumbull, a memory care assisted living community, located at 2415 Reservoir Ave., will host the following complimentary events in February. Call 203-935-8530 to RSVP.

Dementia Live Experience Thursday, Feb. 6, from 4 to 8 p.m. Presented by Right at Home, Caregivers are invited to reserve a time slot to step inside the body and mind of dementia. This powerful virtual experience will allow caregivers to see, hear and feel what life is like for someone living with dementia. Caregivers may bring their loved ones with memory loss to enjoy an activity with Bridges residents during this seminar. Refreshments will be served.

Caregiver Support Group Wednesday, Feb. 19, at 5:30 p.m. Caregivers are invited to trade tips, socialize with others on a similar journey and receive expert advice from dementia care professionals who understand their challenges and concerns. Dinner will be served. Caregivers may bring their loved ones with memory loss to dine with Bridges residents while they attend the group.

Dine and Discover Stem Cell Therapy for Stroke and Traumatic Brain Injury (TBI) Patients: Thursday, Feb. 20, at 5 p.m.; With Guest Speaker Dr. Peter McAllister, co-founder and Chief Medical Officer, New England Institute for Clinical Research. Stroke and traumatic brain injury strike millions of people each year. Dr. McAllister will discuss the various treatment options for the long-term effects of these conditions, including weakness, spasticity, language and cognitive difficulties and pain. He'll also discuss new research on stem cell therapy that could help restore function for stroke and TBI patients. Caregivers may bring their loved ones with memory loss to enjoy a meal and an activity with Bridges by EPOCH residents during this seminar. Dinner will be served.

See the original post:
Dementia Live and 'Stem Cell Therapy for Stroke and Traumatic Brain Injury Patients' seminars - Trumbull Times

THE MENA summit to explore innovation in the liberal arts – Times Higher Education (THE)

The value of a liberal arts education has become a pivotal discussion within the global higher education sector over the last decade. No longer confined to the hallowed halls of ivy-covered American colleges, this multidisciplinary approach, which focuses on developing creative thinking skills, has begun to transform the curricula of institutions worldwide.

To examine this further, the Times Higher Education 2020 MENA Summit, taking place at NYU Abu Dhabi on 10-12 March, will explore the benefits and challenges of broadening the liberal arts educational model across Middle Eastern and North African countries.

Fostering discussions on how to prepare students for a variety of career paths after graduation is high on the list of the summits objectives. Hoda Mostafa, director of the Center for Learning and Teaching at the American University in Cairo, will share useful practices to facilitate the leap between an interdisciplinary education and careers both in and out of academia.

Wasif Rizv,founding president of Habib University, Pakistans first liberal arts and science institution, will provide an instructional model from south-east Asia to demonstrate how a liberal arts education can develop talent to meet the demands of a global workforce.

Another key focus will be enhancing the research culture in countries where talent attraction has faced challenges. Rana Dajani, associate professor at Hashemite University, who established stem cell research ethics law in Jordan, will debate with other panellists which tools are needed to support the next generation of researchers in the MENA region.

Safwan Masri, the current vice-president for Global Centers and Global Development at Columbia University, who has written extensively on the role of Tunisia in the Arab Spring, will deliver the summits closing keynote, underlining the power of research and knowledge transfer in the region to ultimately promote a greater cultural understanding and bridge political boundaries.

The summit will include an exclusive THE rankings masterclass that will dissect the methodology behind the World University Rankings, giving an analysis of the MENA regions successes and future opportunities. Additionally, delegates will enjoy a deep-dive into THEs new University Impact Rankings, which are based on universities successes in working towards the United Nations Sustainable Development Goals.

John Gill, editor of THE, said: We are at a crucial moment for the world on numerous fronts from how to respond to global threats such as climate change, to how to navigate a path to greater understanding and collaboration. Higher education and research will play crucial roles in finding the answers.

At this summit, we will discuss the role of liberal arts education, at a time of debate about how best to prepare students for the new economy, and how to support societies in transition. We will consider how a global perspective can transform the impact of education, and address the interplay between education and research in the MENA region. These topics touch on every aspect of what universities do, as institutions that educate, create new knowledge, and drive economic and social progress, so we are delighted to have such a diverse programme of speakers, and to be meeting at NYU Abu Dhabi, itself a great example of innovation.

The Times Higher Education 2020 MENA Universities Summit will take place 10-12 March at NYU Abu Dhabi. Find out more.

Link:
THE MENA summit to explore innovation in the liberal arts - Times Higher Education (THE)

Global Stem Cell and Primary Cell Culture Medium Market Technology, Development, Trends and Forecasts to 2026 – Instant Tech News

Report of Global Stem Cell and Primary Cell Culture Medium Market is generated by Orbis Research providing the comprehensive study of the industry. Orbis Research is considering the year 2019 as a base year and forecast period for predicting the growth of the market is 2020-2026. Orbis Research is delivering the reports of market research on several categories by an organized method of judging the client, examining market supply, researching, struggle and demand, accompanied by integrating the feedback of the client.

Request a Sample Copy of this [emailprotected]https://www.orbispharmareports.com/sample-request/5800

The Stem Cell and Primary Cell Culture Medium report is a detailed study about top manufacturers, their revenue share, data, deals income, purchaser volume and deal volume. The report, at first, introduces markets classifications, applications definitions, and market overview; product specifications; manufacturing processes; cost structures, raw materials and so on. It exhibits the records that Stem Cell and Primary Cell Culture Medium has set in past and is expected to set in the forthcoming years, despite of the altering market trends and fluctuations.

The market reports are developed on the basis of specific parameters. The report dedicatedly cater professional solutions for corporate strategic decision-making. It adopts global scientific management system, catering top-notch consulting services to clients. Delving into the report, meticulous market revenues and shares growth patterns, analysis of market trends, and the value and volume of the market is mentioned.

Key Players listed in the report are:

MerckSTEMCELL TechnologiesIrvinesciCell Applications, IncBiological IndustriesMiltenyi BiotecSwiss Medica ClinicPromocellCreative BiolabsLifeline Cell TechnologyScienCell Research LaboratoriesOsiris TherapeuticsNuVasiveChiesi PharmaceuticalsJCR PharmaceuticalPharmicellMedi-postAnterogenMolmedTakeda (TiGenix)

Global Stem Cell and Primary Cell Culture Medium Sales Growth Rate Comparison by Type

Liquid MediaPowder Media

Stem Cell and Primary Cell Culture Medium Sales Comparison by Application:

Biopharmaceutical ManufacturingTissue Engineering & Regenerative MedicineGene TherapyOther

The market report follows amalgamation of methodological research and structured methodology. These methods probe into markets with help of thorough research and analysis. In general, the research is defined as extracted information from various sources such as vendors, products, research papers, manufacturers and more. The analysis part is inclusive of quantitative and qualitative analysis of markets such as market forecasts, market segmentations, business models, and many more. Each market study offers equal importance to its prominent manufacturers who operate the market. For budding entrepreneurs, investors and organizations, the detailed analysis of manufacturers is essential. To retain in the competitive landscape, manufacturers also require detailed information of other manufacturers business strategies, models, revenue growth and all other crucial information.

Moreover, the report describes the segmentation of market based on various parameters and attributes. Market segmentation is based on geography, demography, types, product, etc. This leads to easy understanding of customers behavior and demand towards a specific market or product. The key aspect covered in market segmentation is regional study. With help of regional analysis, marketers and investors can get clear idea of business opportunities, potential revenue generation and upcoming opportunities residing in the coming years. For a global business expansion or a regional business establishment, this information have immense effect.

To make an enquiry on [emailprotected] https://www.orbispharmareports.com/enquiry-before-buying/5800

Furthermore, the Stem Cell and Primary Cell Culture Medium report highlights the North American and European region. As these regions leads the most market or the most prominent ones, have extreme importance when setting up a business or expanding it. The report has given description about these regions developing trends, marketing channels which are mostly preferred, investment feasibility for long-term investments and environmental analysis. It is also consists capacity, product price, profit, supply, demand, production and market growth rate and forecast etc. The report also comprise other developing economies market demand and the causes which triggered this demand. It also covers detailed information of market price and size of other key regions which includes South America, Asia, Europe and Middle East.

The Stem Cell and Primary Cell Culture Medium report covers all the potential aspects of a market and provides a brief conclusion to its readers.

Table of Contents

Chapter One: Stem Cell and Primary Cell Culture Medium Market Overview

1.1 Product Overview and Scope of Stem Cell and Primary Cell Culture Medium

1.2 Stem Cell and Primary Cell Culture Medium Segment by Type

1.2.1 Global Stem Cell and Primary Cell Culture Medium Production Growth Rate Comparison by Type 2020 VS 2026

1.2.2 Gas Stem Cell and Primary Cell Culture Medium

1.2.3 Electric Stem Cell and Primary Cell Culture Medium

1.3 Stem Cell and Primary Cell Culture Medium Segment by Application

1.3.1 Stem Cell and Primary Cell Culture Medium Consumption Comparison by Application: 2020 VS 2026

1.3.2 Quick Service Restaurants (QSR)

1.3.3 Full Service Restaurant/Main Line Dining

1.3.4 Retail Outlets

1.3.5 Others

1.4 Global Stem Cell and Primary Cell Culture Medium Market by Region

1.4.1 Global Stem Cell and Primary Cell Culture Medium Market Size Estimates and Forecasts by Region: 2020 VS 2026

1.4.2 North America Estimates and Forecasts (2015-2026)

1.4.3 Europe Estimates and Forecasts (2015-2026)

1.4.4 China Estimates and Forecasts (2015-2026)

1.4.5 Japan Estimates and Forecasts (2015-2026)

1.5 Global Stem Cell and Primary Cell Culture Medium Growth Prospects

1.5.1 Global Stem Cell and Primary Cell Culture Medium Revenue Estimates and Forecasts (2015-2026)

1.5.2 Global Stem Cell and Primary Cell Culture Medium Production Capacity Estimates and Forecasts (2015-2026)

1.5.3 Global Stem Cell and Primary Cell Culture Medium Production Estimates and Forecasts (2015-2026)

Browse full sample [emailprotected]http://www.orbispharmareports.com/2020-2026-global-stem-cell-and-primary-cell-culture-medium-market-in-depth-research-report/

About Us:

Orbis Research (orbisresearch.com) is a single point aid for all your market research requirements. We have vast database of reports from the leading publishers and authors across the globe. We specialize in delivering customized reports as per the requirements of our clients. We have complete information about our publishers and hence are sure about the accuracy of the industries and verticals of their specialization. This helps our clients to map their needs and we produce the perfect required market research study for our clients.

Contact Us:Hector CostelloSenior Manager Client Engagements4144N Central Expressway,Suite 600, Dallas,Texas 75204, U.S.A.Phone No.: USA: +1 (972)-362-8199 | IND: +91 895 659 5155Email ID: [emailprotected]

Originally posted here:
Global Stem Cell and Primary Cell Culture Medium Market Technology, Development, Trends and Forecasts to 2026 - Instant Tech News

Current research: 2020 Latest Report on Exosome Diagnostics Market Report Technologies, Analyze the Pipeline Landscape and Key Companies – WhaTech…

Exosome Diagnostics Market Report analysis including industry Overview, Country Analysis, Key Trends, Key Retail Innovations, Competitive Landscape and Sector Analysis for upcoming years.

ReportsnReports added a new report on The Exosome Diagnostics Market Technologies report delivers the clean elaborated structure of the Report comprising each and every business related information of the market at a global level. The complete range of information related to the Exosome Diagnostics Market Technologies is obtained through various sources and this obtained the bulk of the information is arranged, processed, and represented by a group of specialists through the application of different methodological techniques and analytical tools such as SWOT analysis to generate a whole set of trade based study regarding the Exosome Diagnostics Market Technologies.

Download a Free PDF Sample of Exosome Diagnostics Market Technologies Research Report at:

http://www.reportsnreports.com/contactme=1781607

Top Companies mentioned in this report are Capricor Therapeutics Inc, Evox Therapeutics Ltd, ReNeuron Group Plc, Stem Cell Medicine Ltd, Tavec Inc, Codiak Biosciences Inc, Therapeutic Solutions International Inc, ArunA Biomedical Inc, Ciloa 85.

This latest report is on Exosome Diagnostics Market Technologies which explores the application of exosome technologies within the pharmaceutical and healthcare industries. Exosomes are small cell-derived vesicles that are abundant in bodily fluids, including blood, urine and cerebrospinal fluid as well as in in vitro cell culture.

These vesicles are being used in a variety of therapeutic applications, including as therapeutic biomarkers, drug delivery systems and therapies in their own right. Research within this area remains in the nascent stages, although a number of clinical trials have been registered within the field.

Exosomes have several diverse therapeutic applications, largely centering on stem cell and gene therapy.

Exosomes have been identified as endogenous carriers of RNA within the body, allowing for the intracellular transportation of genetic material to target cells.

As such, developers have worked to engineer exosomes for the delivery of therapeutic miRNA and siRNA-based gene therapies. As RNA is highly unstable within the body, a number of different biological vector systems have been developed to enhance their transport within the circulation, including viruses and liposomes.

Similarly, exosomes derived from stem cells have also been identified for their therapeutic applications, particularly in the treatment of cancer and cardiovascular disease. Exosome technologies offer several advantages over existing biologic-based drug delivery systems.

Reasons to buy this Report:

Develop a comprehensive understanding of exosome technologies and their potential for use within the healthcare sector, Analyze the pipeline landscape and gain insight into the key companies investing in exosomes technologies, Identify trends in interventional and observational clinical trials relevant to exosomes.

Get this Report @ http://www.reportsnreports.com/purchasme=1781607

Scope of this Report:

What are the features of the exosome lifecycle?,How are therapeutic exosomes prepared?,How do exosome therapies in development differ in terms of stage of development, molecule type and therapy area?,Which companies are investing in exosome technologies?,How many clinical trials investigate exosomes as biomarkers, therapeutics and vectors?

Table of contents for Exosome Diagnostics Market Technologies:

1 Table of Contents 4

1.1 List of Tables 6

1.2 List of Figures 7

2 Exosomes in Healthcare 8

2.1 Overview of Exosomes 8

2.2 Drug Delivery Systems 9

2.2.1 Modified Release Drug Delivery Systems 9

2.2.2 Targeted Drug Delivery Systems 10

2.2.3 Liposomes 12

2.2.4 Viruses 14

2.2.5 Exosomes 17

2.3 The Exosome Lifecycle 18

2.4 Exosomes in Biology 18

2.5 Exosomes in Medicine 19

2.5.1 Biomarkers 19

2.5.2 Vaccines 20

2.6 Exosomes as a Therapeutic Target 20

2.7 Exosomes as Drug Delivery Vehicles 21

2.8 Therapeutic Preparation of Exosomes 21

2.8.1 Isolation and Purification 22

2.8.2 Drug Loading 22

2.8.3 Characterization 23

2.8.4 Bioengineering 23

2.8.5 Biodistribution and In Vivo Studies 23

2.8.6 Advantages of Exosome Therapies 24

2.8.7 Disadvantages of Exosome Therapies 24

2.9 Exosomes in Therapeutic Research 25

2.9.1 Exosome Gene Therapies 25

2.9.2 Exosome in Stem Cell Therapy 26

2.10 Exosomes in Oncology 27

2.10.1 Immunotherapy 27

2.10.2 Gene Therapy 28

2.10.3 Drug Delivery 29

2.10.4 Biomarkers 30

2.11 Exosomes in CNS Disease 30

2.11.1 Tackling the Blood-Brain Barrier 30

2.11.2 Exosomes in CNS Drug Delivery 31

2.11.3 Gene Therapy 32

2.12 Exosomes in Other Diseases 33

2.12.1 Cardiovascular Disease 33

2.12.2 Metabolic Disease 33

3 Assessment of Pipeline Product Innovation 36

3.1 Overview 36

3.2 Exosome Pipeline by Stage of Development and Molecule Type 36

3.3 Pipeline by Molecular Target 37

3.4 Pipeline by Therapy Area and Indication 38

3.5 Pipeline Product Profiles 38

3.5.1 AB-126 - ArunA Biomedical Inc. 38

3.5.2 ALX-029 and ALX-102 - Alxerion Biotech 39

3.5.3 Biologics for Autism - Stem Cell Medicine Ltd 39

3.5.4 Biologic for Breast Cancer - Exovita Biosciences Inc. 39

3.5.5 Biologics for Idiopathic Pulmonary Fibrosis and Non-alcoholic Steatohepatitis - Regenasome Pty 39

3.5.6 Biologic for Lysosomal Storage Disorder - Exerkine 39

3.5.7 Biologics for Prostate Cancer - Cells for Cells 40

3.5.8 CAP-2003 - Capricor Therapeutics Inc. 40

3.5.9 CAP-1002 - Capricor Therapeutics Inc. 41

3.5.10 CIL-15001 and CIL-15002 - Ciloa 42

3.5.11 ExoPr0 - ReNeuron Group Plc 42

3.5.12 MVAX-001 - MolecuVax Inc. 43

3.5.13 Oligonucleotides to Activate miR124 for Acute Ischemic Stroke - Isfahan University of Medical Sciences 44

3.5.14 Oligonucleotides to Inhibit KRAS for Pancreatic Cancer - Codiak BioSciences Inc. 44

3.5.15 Proteins for Neurology and Proteins for CNS Disorders and Oligonucleotides for Neurology - Evox Therapeutics Ltd 44

3.5.16 TVC-201 and TVC-300 - Tavec Inc. 45

4 Assessment of Clinical Trial Landscape 48

4.1 Interventional Clinical Trials 48

4.1.1 Clinical Trials by Therapy Type 48

4.1.2 Clinical Trials by Therapy Area 49

4.1.3 Clinical Trials by Stage of Development 50

4.1.4 Clinical Trials by Start Date and Status 50

4.2 Observational Clinical Trials 51

4.2.1 Clinical Trials by Therapy Type 51

4.2.2 Clinical Trials by Therapy Area 51

4.2.3 Clinical Trials by Stage of Development 52

4.2.4 Clinical Trials by Start Date and Status 53

4.2.5 List of All Clinical Trials 54

5 Company Analysis and Positioning 67

5.1 Company Profiles 67

5.1.1 Capricor Therapeutics Inc. 67

5.1.2 Evox Therapeutics Ltd 72

5.1.3 ReNeuron Group Plc 73

5.1.4 Stem Cell Medicine Ltd 77

5.1.5 Tavec Inc. 78

5.1.6 Codiak Biosciences Inc. 80

Read more here:
Current research: 2020 Latest Report on Exosome Diagnostics Market Report Technologies, Analyze the Pipeline Landscape and Key Companies - WhaTech...

Improve Sexual Function for Men: Get the Latest Research in Erectile Dysfunction – Newswire

Improving sexual functioning in men is the subject of a new podcast episode released by men's life coach Anthony Treas from STRONG Men Coaching.

(Newswire.net -- February 4, 2020) -- Improving sexual functioning in men is the subject of a new podcast episode released by men's life coach Anthony Treas from STRONG Men Coaching. This podcast episode discusses with Dr. Brandeis ways to treat problems such as erectile dysfunction in men.

Anthony Treas of STRONG Men Coaching launched a new podcast episode on improving sexual function in men, with Dr. Judson Brandeis.

The podcast can be accessed here: https://strongmenpodcast.com/dr-judson-brandeis

Dr. Brandeis understands that physical intimacy is an important part of a joyful life for men, and he uses innovative medical technology to assist in improving sexual function. He is a Urologist and Director of Clinical Excellence for GAINSWave, a safe shock-wave treatment, who also uses AFFIRM nitric oxide supplementation to significantly improve mens sexual functioning.

Anthony Treas believes that many men are embarrassed to talk with their doctor, or even significant other, about sexual functioning and problems such as Erectile Dysfunction (ED). With the launch of this podcast, men are empowered by understanding the latest research and how they can confidently discuss sexual functioning issues with their doctor.

With the launch of this podcast episode, Dr. Brandeis details the various ways, at different ages, that ED can be treated and sexual health and penile functioning can be improved. Platelet-rich Plasma injections, checking and treating testosterone levels, penis pumps and psychological considerations, along with aforementioned GAINSWave treatment and nitric oxide boosting supplementation, are also discussed.

Some men may have been feeling unfulfilled and unhappy with their life, health and relationships, for several years. Improving sexual functioning using appropriate treatment methods, whilst addressing any other issues through men's coaching sessions, are important considerations for men who are looking to become more confident and successful in all areas of their lives.

Mr. Treas stated that If a man is not happy with himself and where he is at in life, then his relationships, career, friendships and most other areas of his life are all impacted in a negative way, but there is hope. A man can make positive lasting changes and feel good again.

This recently released podcast episode reveals the latest research in how men can improve their sexual functioning and to encourage men to discuss this topic further with their doctor.

Click on the URL above for the podcast, and for more about STRONG Men Coaching go to https://strongmencoaching.com.

See original here:
Improve Sexual Function for Men: Get the Latest Research in Erectile Dysfunction - Newswire

AgeX Therapeutics to Collaborate with University of California, Irvine on Neural Stem Cell Research Program for Huntingtons Disease and Other…

AgeX Therapeutics, Inc. ("AgeX"; NYSE American: AGE), a biotechnology company focused on developing therapeutics for human aging and regeneration, announced a research collaboration with the University of California, Irvine (UCI) using AgeXs PureStem technology to derive neural stem cells, with the goal of developing cellular therapies to treat neurological disorders and diseases for which there are no cures. The collaborations initial R&D work, expected to take approximately one year, will be conducted in the UCI laboratory of Leslie Thompson, PhD, Chancellors Professor of Psychiatry & Human Behavior and Neurobiology & Behavior, a leading researcher in the field of Huntingtons disease and other neurological disorders, under a Sponsored Research Agreement handled by the Industry Sponsored Research team at UCI Beall Applied Innovation. The initial focus will be on Huntingtons disease, while other potential targets may include Parkinsons, Alzheimers, and stroke.

The primary goal of the research will be to develop a robust method of deriving neural stem cells from pluripotent stem cells in sufficient quantity and with sufficient purity and identity for use in cell-based therapy. Professor Thompsons laboratory has already accumulated safety and efficacy animal data that may support an IND submission to the FDA as early as 2021 for the commencement of clinical trials to treat Huntingtons disease.

"We look forward to utilizing AgeXs cell derivation and manufacturing PureStem technology, with its many potential advantages, including industrial scalable manufacturing, lower cost of goods, and clonal cells with high purity and identity. Our goal is to have an improved neural stem cell production method ready within a year to move into clinical development," said Professor Thompson.

"We are absolutely delighted to start this exciting collaboration with Professor Thompson, who has worked tirelessly over her career to develop a neural stem cell product candidate for Huntingtons disease and who has already generated preclinical animal data that may support the initiation of clinical studies," said Dr. Nafees Malik, Chief Operating Officer of AgeX. "Moreover, we are very excited to be entering the field of neurology, which has huge clinical and commercial potential. Neural stem cells may be very useful in other neurological disorders that are common in aging demographics, such as Parkinsons, Alzheimers and stroke."

"This is an example of the kind of collaboration we will be seeking under our newly-unveiled collaboration and licensing strategy, which is to run parallel to our in-house product development," said Dr. Greg Bailey, Chair of AgeX. "We will be collaborating with a world leader in their field on a research project which is close to the clinic."

The collaboration includes an opportunity for AgeX to organize a company to be jointly owned with Professor Thompson and other researchers to pursue clinical development and commercialization of cell therapies derived using licensed inventions arising from the research program, as well as certain patent pending technology for neural stem cell derivation, and certain technical data, including animal data, to support IND submissions.

About AgeX Therapeutics

AgeX Therapeutics, Inc. (NYSE American: AGE) is focused on developing and commercializing innovative therapeutics for human aging. Its PureStem and UniverCyte manufacturing and immunotolerance technologies are designed to work together to generate highly-defined, universal, allogeneic, off-the-shelf pluripotent stem cell-derived young cells of any type for application in a variety of diseases with a high unmet medical need. AgeX has two preclinical cell therapy programs: AGEX-VASC1 (vascular progenitor cells) for tissue ischemia and AGEX-BAT1 (brown fat cells) for Type II diabetes. AgeXs revolutionary longevity platform induced Tissue Regeneration (iTR) aims to unlock cellular immortality and regenerative capacity to reverse age-related changes within tissues. AGEX-iTR1547 is an iTR-based formulation in preclinical development. HyStem is AgeXs delivery technology to stably engraft PureStem cell therapies in the body. AgeX is developing its core product pipeline for use in the clinic to extend human healthspan and is seeking opportunities to establish licensing and collaboration agreements around its broad IP estate and proprietary technology platforms.

Story continues

For more information, please visit http://www.agexinc.com or connect with the company on Twitter, LinkedIn, Facebook, and YouTube.

Forward-Looking Statements

Certain statements contained in this release are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not historical fact including, but not limited to statements that contain words such as "will," "believes," "plans," "anticipates," "expects," "estimates" should also be considered forward-looking statements. Forward-looking statements involve risks and uncertainties. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the business of AgeX Therapeutics, Inc. and its subsidiaries particularly those mentioned in the cautionary statements found in more detail in the "Risk Factors" section of AgeXs Annual Report on Form 10-K and Quarterly Reports on Form 10-Q filed with the Securities and Exchange Commissions (copies of which may be obtained at http://www.sec.gov). Further, in the case of AgeXs new neural stem cell program there can be no assurance that: (i) any new cell derivation methods will be invented in the sponsored research program, (ii) any derivation methods that may be developed will be sufficient to derive neural stem cells in quantities and of purity suitable for clinical use and commercialization, (iii) that any new inventions or existing technology will be licensed on commercially favorable terms, (iv) that any neural stem cells derived for therapeutic use will be shown to be safe and effective in clinical trials, and (v) that any neural stem cells derived for therapeutic use will be successfully commercialized even if clinical trials are successful. Subsequent events and developments may cause these forward-looking statements to change. AgeX specifically disclaims any obligation or intention to update or revise these forward-looking statements as a result of changed events or circumstances that occur after the date of this release, except as required by applicable law.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200203005261/en/

Contacts

Media Contact for AgeX: Bill Douglass Gotham Communications, LLC bill@gothamcomm.com (646) 504-0890

View post:
AgeX Therapeutics to Collaborate with University of California, Irvine on Neural Stem Cell Research Program for Huntingtons Disease and Other...

PRP: Cost, Side Effects, and Recovery

Platelet-rich plasma, or PRP, is a substance thats thought to promote healing when injected. Plasma is a component of your blood that contains special factors, or proteins, that help your blood to clot. It also contains proteins that support cell growth. Researchers have produced PRP by isolating plasma from blood and concentrating it.

The idea is that injecting PRP into damaged tissues will stimulate your body to grow new, healthy cells and promote healing. Because the tissue growth factors are more concentrated in the prepared growth injections, researchers think the bodys tissues may heal faster.

The treatment hasnt been definitively proven. It also hasnt been approved as a treatment by the U.S. Food and Drug Administration. However, famous athletes like Tiger Woods and tennis star Rafael Nadal have been known to use these injections to help heal injuries.

Researchers are trying out PRP injections across a number of applications. Examples of these include:

Hair loss: Doctors have injected PRP into the scalp to promote hair growth and prevent hair loss. According to research from 2014, PRP injections are effective in treating androgenic alopecia, which is also known as male pattern baldness.

Tendon injuries: Tendons are tough, thick bands of tissue that connect muscle to bone. They are usually slow to heal after injury. Doctors have used PRP injections to treat chronic tendon problems, such as tennis elbow, Achilles tendonitis at the ankle, and jumpers knee, or pain in the patellar tendon in the knee.

Acute injuries: Doctors have used PRP injections to treat acute sports injuries, such as pulled hamstring muscles or knee sprains.

Postsurgical repair: Sometimes doctors use PRP injections after surgery to repair a torn tendon (such as a rotator cuff tendon in the shoulder) or ligaments (such as the anterior cruciate ligament, or ACL).

Osteoarthritis: Doctors have injected PRP into the knees of people with osteoarthritis. A 2015 study found that PRP injections were more effective than hyaluronic acid injections (a traditional therapy) for treating osteoarthritis. However, the trial was a small group of 160 people, so larger trials are needed for this to be conclusive.

Its important to note that none of these uses have been definitively proven to provide results.

Read more: 5 exercises for rotator cuff pain

Generally speaking, there are few steps to preparing for PRP injections.

However, PRP can be injected in different ways. For example, sometimes a topical numbing lidocaine solution is applied to your scalp before injection. You may have to arrive early to a treatment session for this to be applied.

Other times, a local anesthetic is mixed with the PRP to reduce any discomfort. Sometimes, your doctor will inject or apply PRP during a surgery. In this instance, preparation for PRP injections would involve following your surgeons recommendations presurgery.

Heres what to expect from a typical PRP injection process:

According to Emory Healthcare, this process usually takes around one hour.

According to the American Academy of Orthopaedic Surgeons, very few insurance plans will provide any reimbursement for PRP injections. The costs must largely be paid out-of-pocket. The costs can also vary from location to location and on how the injections are used. Some of the reported costs nationwide include the following:

Insurance companies consider PRP an experimental treatment. More scientific research will have to conclude its effectiveness before it is more widely covered.

Because PRP involves injecting a substance into the skin, there are potential side effects. PRP is autologous, which means it contains substances that come directly from your own body. This reduces the risks for an allergic reaction that can occur from injecting other medications, such as cortisone or hyaluronic acid. However, there are risks from the injection itself, including:

You should discuss these potential risks with your doctor, as well as the steps your doctor will take to minimize these risks.

When PRP is injected following injury, your doctor may recommend that you rest the affected area. However, these recommendations are more related to the injury and less to the PRP injections. Most people can continue their daily activities following PRP injections.

Because PRP injections are intended to promote healing or growth, you may not notice an immediate difference after receiving the injections. However, in several weeks or months, you may observe that the area is healing faster or growing more hair than you would have expected if you hadnt received PRP injections.

See the rest here:
PRP: Cost, Side Effects, and Recovery

Platelet-Rich Plasma: Does It Work? – www.PainScience.com

An interesting treatment idea for arthritis, tendinopathy, muscle strain and more

PaulIngraham, updated Jan 25, 2020

Give your blood toyourself!

Blood therapy, anyone? Platelet-rich plasma (PRP) injections bathe troubled cells in a concentrated mixture made from your own blood. Hopefully this stimulates healing where it is otherwise failing especially stubborn, slow-motion injuries like tendinitis1 but no one really knows for sure yet.

Despite all the not-knowing, its easy to pay someone to do this for you these days: extract some of your blood, spin it in a centrifuge to get the platelets, and then pump them back into you. Its not cheap, but PRP injections have become super popular, particularly with elite athletes (ever the guinea pigs for unproven, expensive new treatments for musculoskeletal injuries). It sounds perfect for injuries like patellofemoral pain, an extremely common pseudo-arthritis of the knee in runners,2 or IT band syndrome, another kind of common runners knee a huge potential market, in other words. In the fall of 2009, ScienceBasedMedicine.org scathingly criticized the marketing of PRP:3

Without any clear evidence of benefit beyond placebo, PRP is now being marketed aggressively as a cure-all for sports injuries. And at about $300 per injection (the NYT reports $2000/treatment), theres plenty of money to be made. a nation-wide marketing initiative has begun, using sports celebrities as guinea pigs.

~ A Case Study In Aggressive Quackery Marketing, Jones (ScienceBasedMedicine.org)

At that time, the problem was that the marketing was irresponsible in light of the lack of evidence. It was a short wait for more. Today, the marketing is irresponsible in light of the evidence we now have

Cynics can stop reading here. You know this doesnt end well. Theres a section summarizing all the major highlights from the literature further along here, but the bottom line is clear: if it works at all, its tricky and unreliable, probably heavily dependent on factors we dont understand and cannot control.

Stem cells are generic cells that do not yet have a job. In theory, they can become what we need them to be, which is a potentially powerful tool in medicine. Stem cell therapy is a broad concept in regenerative medicine, and it is a hot hot hot topic right now.

Stem cell therapy is identical in spirit to the other two main regenerative therapies in musculoskeletal and pain medicine: platelet-rich plasma and autologous chondrocyte implantation. But neither PRP or ACI is technically a stem cell therapy they use mature, specialized cells, so they are just cell therapies.

But regeneration is the goal of all of these methods, and the topic of stem cell therapy overlaps so much with PRP and ACI that they are practically the same thing regards to safety, efficacy, and the concerns of skeptical consumers and regulators. They are biologically intriguing treatments that might amount to something someday after all, we know regeneration is possible, thanks to salamanders! but its a depressing mess so far, instead of being inspiring and promising. These treatments are all being rushed to market in the same way, all sold as high-tech medicine to desperate consumers long before the science is done.

Meet the Clotters! Platelets are the major clotting tool in your blood, and they are curious critters, neither cells nor molecules, but a strange hybrid often called cell fragments: platelets are to blood cells what wood chips are to a log if the chips were extremely clever. Platelets have a bunch of interesting biological features, but they are best known for their work in clotting and thats mainly what gives them that healing mystique.

There are countless biochemical factors that regulate healing its complex, to say the least. Platelets are part of that equation, playing a critical role in tissue repair and regeneration; specifically they regulate fundamental mechanisms involved in the healing process including cellular migration, proliferation, and angiogenesis.4 Since they are involved in healing, more of them must be good, right?

That is the basic rationale for PRP.

The ruffled white one in the middle is a platelet an activated platelet, specifically. When calm, they are smaller &smoother.

In fact, PRP is often called regenerative medicine, because the idea of genuinely accelerated healing is so tantalizing, happy science fiction. But its more marketing than biology, surprise surprise.5 You could probably talk people into drinking a platelet smoothie if you told them it would regenerate them.

But it is not safe to assume a soup of platelets is regenerative. In fact, its not even safe to assume its safe

Health Canada isnt a fan, and notably they have safety concerns:6

Many emerging autologous cell therapy products may eventually prove to be safe and effective. However, most of these products are currently at the investigational stage of development with an on-going need to gather supporting scientific evidence.

Injecting medications into muscles might not be harmless. (No ones surprised by that, right? Good!) Anaesthetics and NSAIDs probably are a little myotoxic poisonous to muscles and theres conflicting evidence about PRP. It might be fine, but its important to bear in mind that faddish new injection treatments are never risk free.

Like a salad spinner

To make PRP, blood is spun in a centrifuge. Different blood components separate intolayers.

Who says more platelets stimulates healing? Is that in the Platelet User Guide? For extra healing, generously apply platelets to wound. Dosage is critical with many medicines. More is not only not always better, its usually worse. Do other cells like being bathed in ten times the normal number of platelets? Or is it a suffocating mess that throws everything off kilter?

Or is it just kind of ho hum?

In PRP marketing and hype, its common to see claims that its a natural treatment because its your own blood being returned to you, see? and what could be safer and healthier than you-stuff? But this is bio-illogical: theres lots of stuff inside of me that I do not want to be extracted, concentrated, and returned! Pick any hormone, for instance: many of those are just as involved in healing as platelets, but too much of most of them is just a disaster.

For instance, there is a disease of excessive iron, hemochromatosis a major component of red blood cells, essential to life, something you could easily think you want a lot of for vitality and healing. And indeed you do, if youre anemic. But chronically absorb too much, and its a serious disease.

What you want in biology is just-right amounts of everything, rarely lots of extra anything. Its really quite odd to assume that a platelet-rich sauce o blood is natural and safe and helpful just because the stuff came from you. Which is why this treatment needs to be tested, not assumed like every treatment.

In a 2018 podcast, I listened to a really credible expert guest boldly state that theres very strong evidence for platelet-rich plasma in osteoarthritis. Thinking I must have missed something, I checked the primary reference in the show notes, which is also still the most recent review of PRP for osteoarthritis. Did it back up the expert?

Not even close!7 As far as I can tell, there is just zero justification for what she said: its not very strong, its actually very weak. It exists, and its technically positive, but its just not compelling.

PRP fans and purveyors will tell you there is good evidence that PRP works, but they are cherry picking from a few studies that worked out in their favour one way or another. A few positive studies never not mean much; indeed, most positive study results are actually just bogus.8

Taken as a whole, the evidence is somewhere between inconclusive and discouraging. Although more research is needed (of course!) enough decent studies have now been done that the evidence reviews have started to come out.They all warn that most of the evidence is poor quality, and they are all basing their conclusions on just barely enough good data. They all emphasize that PRP methods are not standardized there are many versions of PRP, all based on speculation, not data.

The bad news got rolling in 2010. The New York Times reported9 (very) bad science news:

Now, though, the first rigorous study asking whether the platelet injections actually work finds they are no more effective than saltwater.

Nothing has improved significantly since. Highlights from the literature since then:

Three high-quality studies (75%) and two low-quality studies showed no significant benefit at the final follow-up measurement or predefined primary outcome score when compared with a control group. One high-quality study (25%) showed a beneficial effect of a PRP injection when compared with a corticosteroid injection (corticosteroid injections are harmful in tendinopathy). Based on the best evidence synthesis, there is strong evidence that PRP injections are not efficacious in chronic lateral epicondylar tendinopathy.

In early 2018, the journal Sports Medicine piled on with a review of six (crappy) studies of PRP for muscle injury (pulled muscles, strains).16 Even the optimistic expert I mentioned above expressed her doubts about PRP for muscle injury.

The promising biological rationale, the positive preclinical findings, and the successful early clinical experience of PRP injections are not confirmed by the recent high-level RCTs.

Meta-analysis is the research technique of pooling data from many studies to boost their statistical power. While often thought of as the pinnacle of scientific credibility, in fact meta-analysis is notoriously fallible. It particularly suffers from the garbage in, garbage out problem: its tough to extract meaningful results from pooled data when all the data sucks. The statistical complexity of such analysis also provides plenty of opportunity for bias-powered abuse and statistical jiggery pokery.

Meta-analysis just aint all its cracked up to be, and must be subjected to the same kind of critical analysis as any other kind of study/paper.

I used to rely on meta-analysis, but they are worse than laws & sausages, ceasing to inspire respect in proportion as we know how they are made.

~ Dr. Mark Crislip, "I Never Meta Analysis I Really Like"

Most of the good news coming from isolated or flawed studies. Isolated positive evidence about over-hyped treatments is a huge red flag, which usually means researchers made errors in their favour. Its the pattern of evidence that counts, and so far the pattern is distinctly bad.

Any hope? Maybe a little. There are different ways of doing PRP, and there different conditions in different stages may respond better or worse. Its biologically plausible that PRP could fail with chronic tendinitis but still succeed with an acute muscle strains, for instance, or even fail with one kind of muscle strain and succeed with another. Hammondetal, an experiment on rats rats were harmed and treated for our edification reported a difference between two kinds of muscle strain. It worked better on a more serious injury, where regeneration of muscle tissue was part of the healing process. PRP might assist with that regenerative process, but have no effect on a less serious strain where no regeneration is occurring.20

But these are faint hopes. In general, one would hope that the methods and conditions tested so far are at least in shouting distance of being the right formula close enough to be at least a little more encouraging.

Initially promising in principle, I predict that PRP will now be mired in trumped-up controversy for years. It will die a slow death, only beaten into submission over many years by a growing pile of underwhelming evidence, while its proponents continue to overconfidently sell the service and defend it from detractors, mainly by betting with dwindling odds that just the right formula can still be proven effective for just the right kind of patient. If so, great: I will be pleased to admit that my prediction was wrong! But Im betting against them for now.

After the centrifuge treatment, platelets are separated from the other components of blood.

My final word on this topic has to be placebo PRP is a perfect storm for it. Its got everything! Bearing in mind that its been thoroughly demonstrated that people get stronger placebo effects from treatment features trivial as a more potent pill colour

I can hardly imagine a better formula for a powerful expectation effect or relief from belief. Unfortunately, despite placebos weirdly good reputation, its powers are quite limited.21 The next time you hear a positive anecdote about PRP, remember: its probably the placebo talking.

The bar for worth a try is fairly high for normal folks. No invasive treatment can qualify for it without being proven at least safe. And you really need clear, consistent evidence of non-trivial benefit across several good trials before anything injected is worth a try. Before that its more like hey, its your knee, dont stab it!

The equation is always different for elite athletes, of course: the slightest edge could be a big deal. But that sword cuts both ways! It might help just a little, and that might matter a lot or it might hurt just a little, and that might matter a lot. Every athlete and coach is going to have a different opinion on whether that risk is worth it.

Five updates have been logged for this article since publication (2014). All PainScience.com updates are logged to show a long term commitment to quality, accuracy, and currency. more

I log any change to articles that might be of interest to a keen reader. Complete update logging started in 2016. Prior to that, I only logged major updates for the most popular and controversial articles.

See the Whats New? page for updates to all recent site updates.

January Added references to a pair of recent meta-analyses plus a sidebar about the problems with meta-analysis.

January Science update. Added a couple new references and did a little organizing and editing while I was at it. PRP for muscle strain is now clearly a big fat nothing burger. I suspect other indications will follow suit as the evidence quality continues to accumulate.

2019 General editing and minor updates. Spelled out the relationship to other cell and stem cell therapies much more clearly than before.

2018 Cited Mascarenhasetal on PRP for osteoarthritis (and its the usual story: garbage in, garbage out, no conclusion, no compelling evidence).

2018 Science update, added new meta-analysis of PRP for muscle strain, Grassietal.

2014 Publication.

Tendinitis versus tendonitis: Both spellings are acceptable these days, but the first is the more legitimate, while the second is just an old misspelling that has become acceptable only through popular use, which is a thing that happens in English. The word is based on the Latin tendo which has a genitive singular form of tendinis, and a combining form that is therefore tendin. (Source: Stedmans Electronic Medical Dictionary.)

Tendinitis vs tendinopathy: Both are acceptable labels for ticked off tendons. Tendinopathy (and tendinosis) are often used to avoid the implication of inflammation that is baked into the term tendinitis, because the condition involves no signs of gross, acute inflammation. However, recent research has shown that inflammation is actually there, its just not obvious. So tendinitis remains a fair label, and much more familiar to patients to boot.

The full text of this paper concludes:

Recent systematic reviews on the topic conclude that there is still a paucity of high-quality data providing sufficient evidence to support or disprove the clinical utility of PRP in symptomatic osteoarthritis of the knee. There is even less clinical evidence supporting its use in other joints or in the treatment of focal osteochondral defects despite the basic science evidence in favor of its use. In addition, not all basic science and clinical studies on PRP have concluded it has positive effects.

So garbage in, garbage out, no real conclusions possible: not enough good data even for the knee, even less for other joints. And theres contradictory evidence.

Read more from the original source:
Platelet-Rich Plasma: Does It Work? - http://www.PainScience.com

Can fasting reverse your ‘biological’ age? It can, according to Goop Lab experts – CNET

Gwyneth Paltrow gets a vampire facial in the fourth episode of Goop Lab.

Netflix's The Goop Lab follows Gwyneth Paltrow and the team that runs her wellness brand, Goop, as they experience various alternative wellness practices, from meeting with a psychic to taking aworkshop about how to orgasm. In The Goop Lab's fourth episode, The Health Span Plan, Paltrow, chief content officer Elise Loehnan and Goop's marketing VP Wendy Lauria explore the societal obsession with antiaging and the often expensive lengths many go to avoid it.

In their quest for eternal youth, members of the Goop staff try several different diets reported to reduce the risk of age-related disease, including fasting, veganism and pescatarianism. Paltrow and her team also set out on a quest to find "more natural" alternatives to plastic surgery and fillers, like facials and acupuncture.

Aging is one of many things that medicine can't stop, so that raises the question: Is there any validity to these diets and treatments? Can you really slow down the aging process with food? That's what The Goop Lab sets out to determine and the results are, surprisingly, somewhat valid.

The Health Span Plan episode explores diets and skincare treatments that claim to have antiaging benefits.

The Goop team chats with Valter Longo, the director of the University of Southern California's Longevity Institute, about the practice of fasting and how it can have positive effects on health. He promotes his fasting mimicking diet in the episode (for which he has a book and a $250 diet kit that Paltrow tries). Notably, the group doesn't talk about other forms of fasting -- such as intermittent fasting or alternate-day fasting -- which can have the same health benefits as Longo's diet.

Paltrow also talks with Morgan Levine, who studies aging at the Yale Department of Pathology. Levine developed a method of calculating a person's "biological age," based on several factors that intend to predict how likely you are to get age-related diseases or be at risk for early death.

Paltrow, Loehnan and Lauria are tested for their biological age before starting a new diet for three weeks. Lauria followed a vegan diet and Loehnan did a pescatarian diet, while Paltrow uses Longo's kit (which includes a nut bar, soup packets and kale crackers -- appetizing, huh?) for a five-day fast.

At the end of the three weeks, all three have their "biological ages" retested. The only person whose age did not "lower" was Lauria.

To round out this antiaging episode, all of the women try three different facial treatments -- acupuncture, facial threading and a vampire facial -- that are supposed to be more natural than using typical dermatological treatments such as skin fillers and Botox injections.

Loehnen tries facial acupuncture, which is reported to boost collagen production. Lauria gets a "facial threading" treatment that involves sewing a plastic thread that dissolves after nine months into her face in an effort to boost collagen and lift the face.

A Goop employee tries facial threading, a less invasive way to get the effect of a face lift.

Finally, Paltrow gets a "vampire facial," which is when a facialist extracts platelet rich plasma from your blood, and then microneedles it into the skin on your face. The PRP is supposed to help the skin resurface and look rejuvenated. Paltrow seems a bit weirded out by the process but notes that there's an "overuse of that stuff," (referring to injections, fillers and plastic surgery), and at least "this is your own blood and not a toxin, it's a more natural way."

Right now, there is a lot of hype surrounding fasting, intermittent fasting and ketosis and how those diets might benefit our overall health. It's not all hype -- there's definitely some sound science here and it's likely to keep expanding.

During the episode, Longo presents his fasting mimicking diet, which involves "tricking" the body into a fasting state while allowing specific amounts of food for at least five days. The idea is to give your body just enough nutrients that it thinks it's fasting, but not so few that you encounter the negative effects of prolonged fasting like a weakened immune system and nutritional deficiencies.

Fasting can help improve your overall health, some studies have shown.

Longo says that his clinical trials on the fasting mimicking diet showed to "reduce risk factors for multiple age-related diseases." That's not totally bunk -- science shows that when you restrict calories for certain periods of time, it does promote longevity. A study on this type of fasting did show that it can be effective in improving health markers that put you at risk for age-related diseases such as BMI, body fat percentage and blood pressure. Fasting can also lower inflammation levels in the body, improve cognitive impairment in miceand can decrease insulin-like growth factor, a hormone linked to cancer. The research is promising.

While Longo's diet might be scientifically sound, I found it hard to wrap my mind around the idea that eating processed, packaged foods for five days could actually be better for you than eating whole, unprocessed foods. Surely you can hit the same macronutrient targets (low carb, low protein and a total of 750-1,000 calories per day) he cites is necessary to "trick your body that it's fasting" with real food?

I'd be interested in seeing studies on groups who do the fasting mimicking diet versus groups that follow a pescatarian diet (as Loehnan did in the show). Also, I'd like to see results in a study of participants who follow the fasting mimicking diet with Longo's food packets and bars versus the same exact macronutrients in whole food form. My guess is that the results could be pretty different.

The facial treatments in the episode are pretty extreme. While they are touted as "more natural" alternatives to plastic surgery or fillers, Goop did not provide much information on why these treatments are "better" for you.

When each practitioner did each treatment, it sounded more like an infomercial about why you should do it, rather than a scientifically backed procedure. The episode lacked real information or science on if these treatments are actually safe, and how they compare to fillers or Botox. No one (at least that we could see) challenged the practitioners about the safety or quality of what was going on.

Facial acupuncture is said to help stimulate the production of collagen in the skin.

The science behind facial acupuncture is promising, but there's still a lot of work to be done. As for the facial threading, aka the noninvasive face lift, a study published in JAMAconcluded that the results of the threading face lift are not effective enough to justify the patient's risk of potential complications from the procedure.

I would describe the facial threading procedure more as a cosmetic procedure and less of a facial treatment. Even though the Goop staff say it's more "natural" than a face lift, it seems pretty invasive to me. You see the doctor literally sew a plastic thread into her face and if that isn't invasive plastic surgery, I don't know what is. Nothing about this treatment says "natural alternative" to me. It just says, "here is another way to get a face lift, and it's temporary."

Goop has long been criticized for presenting highly inaccessible treatments, and that's the same in this episode. The vampire facial costs over $1,000, and the facial threading pricing can start at $1,500 and go up to over $4,000. Facial acupuncture is typically less expensive, but it depends on where you go and how many treatments you get.

There's nothing wrong with showing what these extreme treatments are like, it makes for entertaining television. But if Goop wanted to better serve its audience, perhaps it would have been more helpful to show more accessible options for natural beauty products, regimens or other useful skincare advice.

This episode of The Goop Lab presents a few valid and several questionable antiaging practices for your body and face. While fasting to improve your overall health is backed up by science, there are plenty of other more accessible and doable ways to improve your health through nutrition, exercise and lifestyle alone.

Focusing on the basics like sleep, drinking water, moving more and lowering stress seems more realistic, and then you can experiment with fasting if you think it could help you. Fasting is not a very accessible wellness trend in that it's difficult to do, you should do it under the supervision of a specialist, certain health conditions can prevent you from doing it and it can be really triggering for someone who has a history of eating disorders.

Because of this, fasting is not my favorite wellness topic to explore, and I would have loved to see Goop cover more of the actual science on the benefits other diets such as pescatarianism and veganism, or even better the benefits of eating more plant-based diet versus a restrictive plan like veganism or vegetarianism.

As for the facial treatments, I found it interesting to see the different procedures on the market, but unrelatable for someone who can't afford to drop $1,000 and up on a treatment. It would have been much more interesting to me if Goop had talked to skincare experts, dermatologists and other pros in the space who can teach people about good skincare regimens, habits, ingredients and explain what clean or natural beauty products can help.

Now playing: Watch this: Impossible Foods CEO talks pork and the future of plant-based...

7:38

The information contained in this article is for educational and informational purposes only and is not intended as health or medical advice. Always consult a physician or other qualified health provider regarding any questions you may have about a medical condition or health objectives.

Continue reading here:
Can fasting reverse your 'biological' age? It can, according to Goop Lab experts - CNET